Abstract
Plasma next generation sequencing (NGS) is a non-invasive method for tumor genomic profiling that offers personalized treatment options via cell free DNA analysis for patients with advanced cancers. Targeted therapies direct activity toward specific functional protein domain(s) to inhibit tumor cell survival. The EGFR protein is comprised of an extracellular domain (ECD) that spans amino acids 1-620 and an intracellular tyrosine kinase domain (TKD) that can be targeted in multiple cancer types. In advanced non-small cell carcinoma (NSCLC), EGFR directed-therapies mainly focus on mutations within the TKD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
